Import ban extended as India's Pan Pharma racks up third FDA warning letter

Pill packet

The FDA posted another warning letter to Pan Pharmaceuticals that further extends an import alert issued last year, effectively keeping in place a ban on the drugmaker’s products in the U.S.

In the latest warning letter to Pan issued Aug. 25, 2016, the regulatory agency reiterated its concerns with the drugmaker’s Vadodara facility that were uncovered during an inspection in Nov.-Dec. 2015, as well as with the company’s response to previous warnings.

Pan was slapped with a warning letter about conditions at the plant last year and prior to that in 2012 for failing to register with the agency.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Pan, which is based in Gujarat, India, appears to be climbing to the top of a long list of Indian drugmakers the FDA has found to have substandard manufacturing processes.

Inspectors touring the site late last year cited Pan for disrepair, including rusty production equipment, contaminants near the manufacturing area, including mold, and building infrastructure that allowed pigeons and lizards into the production area. 

FDA inspectors also found rodent droppings within three feet of bags said to contain drug product. When confronted by inspectors about the conditions, a Pan spokesman “told our investigator that your firm had no cleaning procedure for the equipment or facility,” the FDA said in the warning letter.

The agency also came down hard on Pan for its poor record-keeping and quality-control systems at the facility.

Indian drugmakers account for a large portion of the generic and OTC medications that U.S. consumers use, about 40%, but the Indian industry also accounts for many of the warning letters and plant bans that the FDA issues. In a survey by Reuters last year, 42 Indian manufacturing facilities were banned from shipping products into the U.S., while 40 facilities in China were on the import ban list.

- here’s the latest FDA warning letter

Related Article:
FDA issues import alert on Pan Pharma, ramping up its pressure on the India drugmaker

Read more on

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.

Lonza will build two new manufacturing suites at its Visp, Switzerland site to handle antibody-drug conjugates for an unnamed customer.